Entrada Therapeutics is finally able to get its Duchenne muscular dystrophy candidate (DMD) back on track after the FDA ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy - - Follows recently received ...

Beqvez was Pfizer's first gene therapy, stemming from an alliance with Spark Therapeutics (now part of Roche) more than a ...

Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...

REGENXBIO (NASDAQ:RGNX – Get Free Report) is anticipated to announce its earnings results before the market opens on Tuesday, ...

Acelyrin stock is down over 18% year-to-date. Solid Biosciences Inc. (11% jump in followers) Solid Biosciences shares surged ...